Johnson & Johnson
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. and Updates Financial Guidance
Summary
Johnson & Johnson (JNJ) has completed the acquisition of Firefly Bio, Inc., a biotechnology company specializing in degrader antibody conjugate (DAC) technology for oncology, for $1 billion in cash. This acquisition, along with a strategic agreement with Sail Biomedicines, is expected to reduce JNJ's adjusted operational earnings per share (EPS) and adjusted EPS by approximately $0.64 in 2026 and $1.36 in 2027. The transaction is expected to dilute adjusted operational EPS and adjusted EPS by approximately $0.46 in 2026 and $0.08 in 2027. The company has updated its full-year 2026 guidance to reflect these impacts.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement